Meunier Solène M, Voegel Clarissa D, Neubert Elisabeth, Harburger Livia A, Riond Barbara, Hofmann-Lehmann Regina, Boretti Felicitas S, Sieber-Ruckstul Nadja S
Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Center for Forensic Hair Analytics, Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.
BMC Vet Res. 2025 Oct 23;21(1):629. doi: 10.1186/s12917-025-05064-5.
Monitoring Cushing's syndrome (CS) in dogs remains a significant challenge and currently relies on clinical signs, biochemistry results and hormone tests, such as prepill or post-ACTH cortisol. Salivary cortisol testing at home, effective in humans, could benefit dogs by minimizing in-hospital fear impacts on cortisol measurements. The objectives of this study were to (1) assess the feasibility of saliva sampling in client-owned dogs and (2) compare at-home and in-hospital salivary cortisol concentrations for monitoring trilostane treatment. Ten healthy controls and 38 trilostane-treated dogs with CS were included in this prospective observational clinical trial. Saliva was collected using a ginger-dipped Salimetrics swab held in the dogs' mouths for 30 seconds. Saliva was collected from controls at the hospital and at home. For trilostane-treated dogs, saliva was collected in the hospital before blood sampling for prepill serum cortisol and at home by owners. Salivary cortisol concentrations were measured using liquid chromatography high-resolution mass spectrometry (LC-HRMS), and serum cortisol by LC-HRMS and chemiluminescence immunoassay. Dogs with CS were classified as well-controlled if clinical signs had resolved.
In-hospital and at-home saliva sampling was successful in all 10 controls, but only in 18/38 (47%) and 7/18 (39%) dogs with CS, respectively. Salivary cortisol was significantly lower at home in CS dogs but not in controls. Among the 7 CS dogs sampled at both locations, the uncontrolled dog had the highest at-home cortisol level. Four of 6 well-controlled dogs had prepill serum cortisol above the target range, with at-home salivary cortisol undetectable in 3 and lower than the uncontrolled dog in one.
Saliva sampling remains challenging in CS dogs. This method needs further refinement before stress-free, at-home salivary cortisol evaluation surpasses current monitoring techniques, such as prepill serum cortisol measurement. Registry: animex-ch, TRN: ZH076/19 and ZH153/22, Registration dates: 27 Juli 2019 and 22 September 2022.
监测犬库欣综合征(CS)仍然是一项重大挑战,目前依赖于临床症状、生化检查结果和激素检测,如服药前或促肾上腺皮质激素(ACTH)刺激后皮质醇检测。在家中进行唾液皮质醇检测,对人类有效,可能会使犬受益,因为可以将住院时的恐惧对皮质醇测量的影响降至最低。本研究的目的是:(1)评估在宠物犬中采集唾液样本的可行性;(2)比较在家中和住院时的唾液皮质醇浓度,以监测曲洛斯坦治疗效果。这项前瞻性观察性临床试验纳入了10只健康对照犬和38只接受曲洛斯坦治疗的CS犬。使用蘸有生姜的Salimetrics拭子放在犬口中30秒来采集唾液。在医院和家中采集对照犬的唾液。对于接受曲洛斯坦治疗的犬,在医院采血检测服药前血清皮质醇之前采集唾液,在家中由主人采集唾液。使用液相色谱高分辨率质谱法(LC-HRMS)测量唾液皮质醇浓度,使用LC-HRMS和化学发光免疫分析法测量血清皮质醇浓度。如果临床症状消失,则将患有CS的犬分类为病情得到良好控制。
在所有10只对照犬中,在医院和在家中采集唾液样本均成功,但在患有CS的犬中,分别只有18/38(47%)和7/18(39%)成功。患有CS的犬在家中的唾液皮质醇显著低于在医院时,但对照犬并非如此。在两个地点都采集了样本的7只患有CS的犬中,病情未得到控制的犬在家中的皮质醇水平最高。6只病情得到良好控制的犬中有4只服药前血清皮质醇高于目标范围,其中3只在家中的唾液皮质醇检测不到,1只低于病情未得到控制的犬。
在患有CS的犬中采集唾液样本仍然具有挑战性。在无应激的家庭唾液皮质醇评估超过当前监测技术(如服药前血清皮质醇测量)之前,这种方法需要进一步完善。注册信息:animex-ch,TRN:ZH076/19和ZH153/22,注册日期:2019年7月27日和2022年9月22日。